These findings imply that EphB4 acts as a tumour suppressor when triggered by its ligand, and that the tumour-promoting actions of Eph receptors may be ligand-independent in this setting, where the Abl–Crk pathway suppresses the growth, migration, and infiltration of breast cancer cells [6]. Here, EPHB4 is linked to breast carcinoma.